| Q93157526 | 4.1B suppresses cancer cell proliferation by binding to EGFR P13 region of intracellular juxtamembrane segment |
| Q24672490 | A comprehensive pathway map of epidermal growth factor receptor signaling |
| Q35832783 | A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinase |
| Q36530153 | A negative feedback loop attenuates EGF-induced morphological changes |
| Q34692050 | A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro |
| Q37634563 | A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway |
| Q36807981 | A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C. |
| Q24310428 | A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1 |
| Q42213336 | Activity of the epidermal-growth-factor receptor and phospholipase C-gamma 1 in heat-stressed fibroblasts and A-431 cells |
| Q41649277 | Alteration of the kinetic properties of the epidermal growth factor receptor tyrosine kinase by basic proteins |
| Q40653709 | Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants |
| Q36619090 | Cancer metastasis and EGFR signaling is suppressed by amiodarone-induced versican V2. |
| Q36233701 | Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis |
| Q24598357 | Cell signaling by receptor tyrosine kinases |
| Q38109021 | Cellular functions regulated by phosphorylation of EGFR on Tyr845. |
| Q36171281 | Cetuximab and biomarkers in non-small-cell lung carcinoma |
| Q33778237 | Co-conserved features associated with cis regulation of ErbB tyrosine kinases |
| Q27323236 | Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation |
| Q40793167 | Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. |
| Q41893499 | Conformational changes accompany phosphorylation of the epidermal growth factor receptor C-terminal domain |
| Q27723532 | Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3 |
| Q30193485 | Disease specificity of kinase domains: the src-encoded catalytic domain converts erbB into a sarcoma oncogene |
| Q40801239 | EGF receptor in neoplasia and metastasis |
| Q50297458 | EGFR autophosphorylation |
| Q33737298 | Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways |
| Q36234800 | Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement |
| Q35687404 | Epidermal growth factor receptor: elements of intracellular communication |
| Q44244056 | Epidermal growth factor receptors: function modulation by phosphorylation and glycosylation interplay |
| Q34914079 | Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity |
| Q24305821 | Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor |
| Q71808981 | In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals |
| Q47815156 | Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras |
| Q36880844 | Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling |
| Q38756858 | Inhibition of autophosphorylation of epidermal growth factor receptor by small peptides in vitro |
| Q30194582 | Involvement of pp60c-src with two major signaling pathways in human breast cancer |
| Q37134352 | Luciferase fragment complementation imaging of conformational changes in the epidermal growth factor receptor |
| Q28484612 | Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression |
| Q40366179 | Mutation of proline-1003 to glycine in the epidermal growth factor (EGF) receptor enhances responsiveness to EGF. |
| Q48142352 | Nucleotide sequence of the C-terminal region of the mouse epidermal growth factor receptor and expression in teratoma-derived cell lines with increased tumorigenic properties |
| Q30441810 | Phosphorylation and activation of epidermal growth factor receptors in cells transformed by the src oncogene |
| Q38609896 | Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail |
| Q37385906 | Positive and negative tissue-specific signaling by a nematode epidermal growth factor receptor |
| Q38470647 | ProKinO: a unified resource for mining the cancer kinome |
| Q42958774 | Receptor-based virtual screening of EGFR kinase inhibitors from the NCI diversity database. |
| Q36235312 | Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase |
| Q37626541 | Rule-based modeling: a computational approach for studying biomolecular site dynamics in cell signaling systems. |
| Q30195496 | SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma |
| Q34504260 | Structural basis for activation of trimeric Gi proteins by multiple growth factor receptors via GIV/Girdin |
| Q36458355 | Structure and dynamics of the epidermal growth factor receptor C-terminal phosphorylation domain |
| Q37197992 | Structure-based view of epidermal growth factor receptor regulation |
| Q33188385 | Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor |
| Q34652403 | Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation |
| Q90533622 | Tamoxifen-Induced Apoptosis of MCF-7 Cells via GPR30/PI3K/MAPKs Interactions: Verification by ODE Modeling and RNA Sequencing |
| Q38201344 | The EGFR family: not so prototypical receptor tyrosine kinases |
| Q29617919 | The ErbB signaling network: receptor heterodimerization in development and cancer |
| Q27646344 | The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain |
| Q34623704 | The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling |
| Q36696910 | The juxtamembrane regions of the epidermal growth factor receptor and gp185erbB-2 determine the specificity of signal transduction |
| Q24307577 | The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor |
| Q24314441 | The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-gamma |
| Q42997940 | Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity |
| Q50297989 | Trans-autophosphorylation of ERBB2 heterodimers |
| Q41674582 | Transmembrane signalling at the epidermal growth factor receptor. Positive regulation by the C-terminal phosphotyrosine residues |
| Q24646756 | Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation |